Compare DDD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | EDIT |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.8M | 233.3M |
| IPO Year | N/A | 2016 |
| Metric | DDD | EDIT |
|---|---|---|
| Price | $1.93 | $2.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $4.75 | $4.13 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $391,651,000.00 | $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | $18.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.32 | $0.91 |
| 52 Week High | $5.00 | $4.54 |
| Indicator | DDD | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 48.30 |
| Support Level | $1.70 | $2.09 |
| Resistance Level | $2.29 | $2.70 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 38.14 | 75.41 |
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.